Abiopharma

🔍 Rengel Michael (Executive)

Company: Arhaus, Inc. (ARHS)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 150,000 shares of Performance Share Units (Derivative)
  Date: 2026-04-15 | Code: A | Expires: 2028-12-31 | equity_swap_involved: 0 | shares_owned_after: 150,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 150,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 150,000.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: Each Performance Share Unit ("PSU") represents a contingent right to receive one share of Class A Common Stock, subject to the achievement of applicable performance criteria over a three-year performance period beginning January 1, 2026 and ending on December 31, 2028. The target number of PSUs is reported in Column 5. The number of shares to be earned and issued may be 0%-200% of the target number of PSUs depending on actual performance.
• F2: Subject to the Reporting Person's continuous employment with the Issuer, the PSUs granted vest on December 31, 2028, but the PSUs will not settle and payout until the number of PSUs earned is determined by the Issuer's Compensation Committee based on the Company's achievement of performance goals.
• F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock, subject to the Reporting Person's continuous service to the Issuer.
• F4: Subject to the Reporting Person's continuous service to the Issuer, the RSUs vest pro rata on the first, second, and third anniversaries of the transaction date (April 15, 2026).